AR113022A1 - Anticuerpo anti-pacap - Google Patents

Anticuerpo anti-pacap

Info

Publication number
AR113022A1
AR113022A1 ARP180102618A ARP180102618A AR113022A1 AR 113022 A1 AR113022 A1 AR 113022A1 AR P180102618 A ARP180102618 A AR P180102618A AR P180102618 A ARP180102618 A AR P180102618A AR 113022 A1 AR113022 A1 AR 113022A1
Authority
AR
Argentina
Prior art keywords
antibodies
pacap antibody
pacap
migraine
compositions
Prior art date
Application number
ARP180102618A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR113022A1 publication Critical patent/AR113022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP180102618A 2017-09-29 2018-09-13 Anticuerpo anti-pacap AR113022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
AR113022A1 true AR113022A1 (es) 2020-01-15

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102618A AR113022A1 (es) 2017-09-29 2018-09-13 Anticuerpo anti-pacap

Country Status (27)

Country Link
US (3) US10519225B2 (https=)
EP (1) EP3688035A1 (https=)
JP (2) JP6952888B2 (https=)
KR (1) KR102453573B1 (https=)
CN (1) CN111164105B (https=)
AR (1) AR113022A1 (https=)
AU (1) AU2018341959B2 (https=)
BR (1) BR112020003628A2 (https=)
CA (1) CA3077304C (https=)
CL (1) CL2020000705A1 (https=)
CO (1) CO2020002170A2 (https=)
CR (1) CR20200127A (https=)
DO (1) DOP2020000060A (https=)
EA (1) EA202090563A1 (https=)
EC (1) ECSP20020293A (https=)
IL (1) IL273529A (https=)
JO (1) JOP20200069A1 (https=)
MA (1) MA50654A (https=)
MX (1) MX2020003563A (https=)
MY (1) MY199876A (https=)
NZ (1) NZ762312A (https=)
PE (1) PE20201494A1 (https=)
PH (1) PH12020550340A1 (https=)
SG (1) SG11202002572YA (https=)
TW (1) TWI701260B (https=)
WO (1) WO2019067293A1 (https=)
ZA (1) ZA202001058B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2023010065A2 (en) * 2021-07-29 2023-02-02 Cephalon Llc Compositions and methods for anti-pacap antibodies
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
KR102839881B1 (ko) * 2021-11-19 2025-07-31 대한민국 방송통신기자재 성능 측정 시스템 및 그 방법
WO2024218541A1 (en) * 2023-04-20 2024-10-24 Mark Hasleton Treatment of migraine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486472A (en) 1990-03-17 1996-01-23 Takeda Chemical Industries, Ltd. Monoclonal antibodies to PACAP
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
US7615219B2 (en) 2003-01-16 2009-11-10 Life Sciences Research Partners Vzw Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
CA2906737C (en) * 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
EP3035950A4 (en) 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
US10822408B2 (en) * 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
BR112020003628A2 (pt) 2020-09-01
CO2020002170A2 (es) 2020-04-01
ZA202001058B (en) 2022-06-29
PE20201494A1 (es) 2020-12-29
CN111164105A (zh) 2020-05-15
AU2018341959A1 (en) 2020-03-05
CA3077304A1 (en) 2019-04-04
TWI701260B (zh) 2020-08-11
US10954292B2 (en) 2021-03-23
JP7221352B2 (ja) 2023-02-13
CA3077304C (en) 2023-08-01
US20200131256A1 (en) 2020-04-30
US10519225B2 (en) 2019-12-31
JOP20200069A1 (ar) 2020-04-28
JP2020535167A (ja) 2020-12-03
SG11202002572YA (en) 2020-04-29
KR20200040881A (ko) 2020-04-20
JP2022000049A (ja) 2022-01-04
MA50654A (fr) 2020-08-05
CR20200127A (es) 2020-04-08
US20190100579A1 (en) 2019-04-04
ECSP20020293A (es) 2020-06-30
IL273529A (en) 2020-05-31
PH12020550340A1 (en) 2022-05-02
MY199876A (en) 2023-11-27
NZ762312A (en) 2022-11-25
EA202090563A1 (ru) 2020-06-24
JP6952888B2 (ja) 2021-10-27
CL2020000705A1 (es) 2020-09-11
EP3688035A1 (en) 2020-08-05
CN111164105B (zh) 2023-07-04
MX2020003563A (es) 2020-08-03
AU2018341959B2 (en) 2021-11-25
TW201920280A (zh) 2019-06-01
DOP2020000060A (es) 2020-08-15
KR102453573B1 (ko) 2022-10-12
WO2019067293A1 (en) 2019-04-04
US20210171616A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
AR113022A1 (es) Anticuerpo anti-pacap
SV2018005662A (es) Moduladores del receptor x farnesoide
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
DOP2017000303A (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
MX378344B (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
BR112018011154A2 (pt) dispersões sólidas compreendendo um estimulador de sgc
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
BR112017004739A2 (pt) ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX385372B (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
PH12017501205A1 (en) Glucagon derivatives
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
BR112018006170B8 (pt) Método e composição para clareamento de pele usando um extrato de cultura celular de earliella scabrosa e seu uso
UY36742A (es) Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona
MX2018003289A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO.
CL2019001924A1 (es) Composición fungicida efectiva contra alternaria en cítricos. (divisional solicitud 201701815)
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)
EA201992616A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ СНИЖЕНИЯ ИММУНОГЕННОСТИ ХИМЕРНЫХ РЕЦЕПТОРОВ Notch
AR099821A1 (es) Método para tratar o reducir la cefalea en un sujeto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal